Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: NTR004
MIFTS: 61

Neutropenia

Categories: Blood diseases, Bone diseases, Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Neutropenia

About this section

MalaCards integrated aliases for Neutropenia:

Name: Neutropenia 11 28 53 5 43 14 36 71 75
Leukopenia 71

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases Infectious diseases
Anatomical: Blood diseases Neuronal diseases Respiratory diseases Bone diseases Immune diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:1227
ICD9CM 34 288.0
MeSH 43 D009503
SNOMED-CT 68 191336001
ICD10 31 D70
UMLS 71 C0023530 C0027947
Sources

Summaries for Neutropenia

About this section

MalaCards based summary: Neutropenia, also known as leukopenia, is related to poikiloderma with neutropenia and cyclic neutropenia. An important gene associated with Neutropenia is ELANE (Elastase, Neutrophil Expressed), and among its related pathways/superpathways are Hematopoietic Stem Cells and Lineage-specific Markers and Other interleukin signaling. The drugs Triamcinolone and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include breast, bone marrow and myeloid, and related phenotypes are immune system and hematopoietic system

Wikipedia: 75 Neutropenia is an abnormally low concentration of neutrophils (a type of white blood cell) in the blood.... more...
Sources

Related Diseases for Neutropenia

About this section

Diseases in the Neutropenia family:

Neutropenia, Chronic Familial Neutropenia, Severe Congenital, 1, Autosomal Dominant
Neutropenia, Severe Congenital, 3, Autosomal Recessive Neutropenia, Severe Congenital, 4, Autosomal Recessive
Neutropenia, Severe Congenital, 2, Autosomal Dominant Neutropenia, Severe Congenital, 5, Autosomal Recessive
Neutropenia, Severe Congenital, 6, Autosomal Recessive Neutropenia, Severe Congenital, 7, Autosomal Recessive
Neutropenia, Severe Congenital, 8, Autosomal Dominant Neutropenia, Severe Congenital, 9, Autosomal Dominant
Severe Congenital Neutropenia Severe Congenital Neutropenia 1
Severe Congenital Neutropenia 7 Autosomal Dominant Severe Congenital Neutropenia
Severe Congenital Neutropenia 2 Severe Congenital Neutropenia 5
Severe Congenital Neutropenia 3 Severe Congenital Neutropenia 6
Severe Congenital Neutropenia 8 Severe Congenital Neutropenia 4
Elane-Related Neutropenia Acquired Neutropenia
Autosomal Recessive Severe Congenital Neutropenia

Diseases related to Neutropenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1183)
# Related Disease Score Top Affiliating Genes
1 poikiloderma with neutropenia 33.5 USB1 JAGN1 HAX1 G6PC3
2 cyclic neutropenia 33.4 USB1 TAFAZZIN SLC37A4 JAGN1 IL3 HAX1
3 severe congenital neutropenia 33.3 VPS13B SRP54 SLC37A4 JAGN1 IL3 HAX1
4 neutropenia, severe congenital, 3, autosomal recessive 33.1 IL3 HAX1 ELANE CSF3R CSF3 CSF2
5 severe congenital neutropenia 4 33.0 SLC37A4 HAX1 G6PC3
6 severe congenital neutropenia 5 33.0 USB1 SLC37A4 JAGN1 HAX1 GFI1 G6PC3
7 severe congenital neutropenia 7 33.0 USB1 SRP54 JAGN1 HAX1 GFI1 G6PC3
8 severe congenital neutropenia 3 32.9 SLC37A4 JAGN1 HAX1 GFI1 G6PC3 ELANE
9 severe congenital neutropenia 6 32.9 JAGN1 G6PC3
10 autosomal dominant severe congenital neutropenia 32.8 SRP54 SLC37A4 JAGN1 HAX1 GFI1 G6PC3
11 felty syndrome 32.8 IL3 FCGR3B CSF3 CSF2
12 3-methylglutaconic aciduria with cataracts, neurologic involvement and neutropenia 32.7 HAX1 CLPB
13 whim syndrome 1 32.6 HAX1 G6PC3 ELANE CSF3R CSF3
14 shwachman-diamond syndrome 1 32.5 SRP54 HAX1 GFI1 G6PC3 ELANE CSF3R
15 autosomal recessive severe congenital neutropenia 32.4 HAX1 G6PC3
16 cohen syndrome 32.4 VPS13B JAGN1 HAX1 G6PC3
17 leukemia, acute lymphoblastic 32.3 TPMT TOP1 IL3 CSF3R CSF3 CSF2
18 leukemia, acute myeloid 32.3 TOP1 IL3 GFI1 FCGR3B CSF3R CSF3
19 thiopurines, poor metabolism of, 1 31.9 UGT1A1 TPMT DPYD
20 granulocytopenia 31.9 IL3 CSF3 CSF2
21 myelodysplastic syndrome 31.7 TOP1 IL3 FCGR3B CSF3R CSF3 CSF2
22 acute leukemia 31.6 TPMT TOP1 IL3 CSF3R CSF3 CSF2
23 mucositis 31.5 IL3 DPYD CSF3 CSF2
24 hematologic cancer 31.5 TOP1 IL3 CSF3 CSF2
25 deficiency anemia 31.5 TPMT IL3 CSF3R CSF3 CSF2
26 aspergillosis 31.5 ELANE CSF3 CSF2
27 myeloid leukemia 31.4 IL3 CSF3R CSF3 CSF2
28 aplastic anemia 31.3 IL3 CSF3R CSF3 CSF2
29 pancytopenia 31.2 TPMT IL3 G6PC3 CSF3 CSF2
30 stomatitis 31.2 DPYD CSF3 CSF2
31 neutrophilia, hereditary 31.1 IL3 CSF3R CSF3 CSF2
32 diarrhea 31.1 UGT1A1 TOP1 IL3 CSF3
33 leukemia, chronic myeloid 31.0 IL3 FCGR3B ELANE CSF3R CSF3 CSF2
34 bacterial infectious disease 30.9 IL3 FCGR3B ELANE CSF3 CSF2
35 dyskeratosis congenita 30.8 USB1 HAX1 CSF3 CSF2
36 paroxysmal nocturnal hemoglobinuria 30.8 IL3 FCGR3B CSF3R CSF3 CSF2
37 skin disease 30.8 TPMT IL3 FCGR3B CSF3 CSF2
38 bacterial pneumonia 30.7 ELANE CSF3 CSF2
39 peritonitis 30.7 FCGR3B ELANE CSF3
40 gastroenteritis 30.6 IL3 CSF3 CSF2
41 myeloproliferative neoplasm 30.6 IL3 CSF3R CSF3 CSF2
42 thrombocytosis 30.5 IL3 CSF3 CSF2
43 chronic myelomonocytic leukemia 30.5 TOP1 IL3 CSF3R CSF3 CSF2
44 acute promyelocytic leukemia 30.4 IL3 ELANE CSF3R CSF3 CSF2
45 severe covid-19 30.4 FCGR3B CSF3 CSF2
46 hemophagocytic lymphohistiocytosis 30.4 FCGR3B CSF3 CSF2
47 granulomatosis with polyangiitis 30.3 TPMT FCGR3B ELANE
48 critical covid-19 30.1 FCGR3B CSF3 CSF2
49 gilbert syndrome 30.0 UGT1A1 TPMT TOP1 DPYD
50 hemorrhagic cystitis 30.0 TOP1 CSF3

Comorbidity relations with Neutropenia via Phenotypic Disease Network (PDN): (show all 47)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Acute Leukemia Agammaglobulinemia, X-Linked
Anemia, Autoimmune Hemolytic Bladder Cancer
Bronchitis Chronic Kidney Disease
Colorectal Cancer Decubitus Ulcer
Deficiency Anemia Esophageal Cancer
Esophageal Candidiasis Esophagitis
Felty Syndrome Female Breast Cancer
Gastric Cancer Granulomatosis with Polyangiitis
Heart Disease Hepatic Encephalopathy
Hydronephrosis Hypersplenism
Hypothyroidism Immune Deficiency Disease
Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1 Intestinal Obstruction
Iron Deficiency Anemia Leukemia, Chronic Lymphocytic
Main Bronchus Cancer Oral Candidiasis
Ovarian Cancer Paralytic Ileus
Plasma Cell Neoplasm Pneumocystosis
Portal Hypertension Postinflammatory Pulmonary Fibrosis
Primary Thrombocytopenia Protein-Energy Malnutrition
Pulmonary Fibrosis and/or Bone Marrow Failure, Telomere-Related, 2 Respiratory Failure
Retinitis Pigmentosa and Erythrocytic Microcytosis Rheumatoid Arthritis
Sideroblastic Anemia Systemic Lupus Erythematosus
Waldenstroem's Macroglobulinemia

Graphical network of the top 20 diseases related to Neutropenia:



Diseases related to Neutropenia
Sources

Symptoms & Phenotypes for Neutropenia

About this section

GenomeRNAi Phenotypes related to Neutropenia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 CLPB CSF2 CSF3 CSF3R DPYD ELANE
2 no effect GR00402-S-2 10.18 CLPB CSF2 CSF3 CSF3R DPYD ELANE

MGI Mouse Phenotypes related to Neutropenia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.73 CSF2 CSF3 CSF3R ELANE FCGR3B G6PC3
2 hematopoietic system MP:0005397 9.44 CSF2 CSF3 CSF3R ELANE FCGR3B G6PC3
Sources

Drugs & Therapeutics for Neutropenia

About this section

Drugs for Neutropenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 361)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
2
Docetaxel Approved, Investigational Phase 4 114977-28-5 148124
3
Teicoplanin Approved, Investigational Phase 4 61036-62-2 16170201
4
Micafungin Approved, Investigational Phase 4 235114-32-6 477468
5
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
6
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
7
Cilastatin Approved, Investigational Phase 4 82009-34-5 6435415
8
Lenalidomide Approved Phase 4 191732-72-6 216326
9
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
10
Daratumumab Approved Phase 4 945721-28-8
11
Ixazomib Approved, Investigational Phase 4 1072833-77-2 25183872
12
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294
13
Doripenem Approved, Investigational Phase 4 148016-81-3 73303
14
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
15
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
16
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
17
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
18
Sulfamethoxazole Approved Phase 4 723-46-6 5329
19
Benzylpenicillin Approved, Vet_approved Phase 4 61-33-6 5904
20
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 441130
21
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
22
Clavulanic acid Approved, Vet_approved Phase 4 58001-44-8 5280980
23
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
24
Ofloxacin Approved Phase 4 82419-36-1 4583
25
Ceftazidime Approved Phase 4 78439-06-2, 72558-82-8 5481173
26
Amikacin Approved, Investigational, Vet_approved Phase 4 37517-28-5, 39831-55-5 37768
27
Simvastatin Approved Phase 4 79902-63-9 54454
28
Ceftolozane Approved, Investigational Phase 4 689293-68-3 75984602
29
Letermovir Approved, Investigational Phase 4 917389-32-3 9916099 45138674
30
Lenograstim Approved, Investigational Phase 4 135968-09-1
31
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
32
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
33
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965
34
Ribavirin Approved Phase 4 36791-04-5 37542
35
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
36
Triamcinolone hexacetonide Phase 4
37
Triamcinolone diacetate Phase 4
38
Triamcinolone Acetonide Phase 4 6436
39 glucocorticoids Phase 4
40 Anti-Inflammatory Agents Phase 4
41
Hydroxyitraconazole Phase 4 108222
42 HIV Protease Inhibitors Phase 4
43 Cilastatin, Imipenem Drug Combination Phase 4
44
protease inhibitors Phase 4
45 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
46 Folate Phase 4
47 Vitamin B9 Phase 4
48 Vitamin B Complex Phase 4
49 Anti-Retroviral Agents Phase 4
50 Folic Acid Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 419)
# Name Status NCT ID Phase Drugs
1 A Pilot Study of Granulocyte Colony-Stimulating Factor Starting at 24 Hours vs 72 Hours in Pediatric Oncology Patients Unknown status NCT03823950 Phase 4 Granulocyte Colony-Stimulating Factor
2 Long-acting Granulocyte Colony Stimulating Factor for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients: A Prospective Cohort Study Unknown status NCT03793205 Phase 4 Long-acting G-CSF;Short-acting G-CSF
3 Prospective Unblinded Randomized Trial to Examine Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia Unknown status NCT02463747 Phase 4 Piperacillin/tazobactam;Ceftazidim;Meropenem;Vancomycin
4 Cost-Effectiveness Study of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor(PEG-rhG-CSF) in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma Unknown status NCT04083079 Phase 4 PEG-rhG-CSF;rhG-CSF
5 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
6 A Prospective, Open, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of PEG-rhG-CSF in Reducing Neutropenia in Patients With Cervical Cancer Unknown status NCT03206684 Phase 4 PEG-rhG-CSF;rhG-CSF
7 Efficacy and Safety in Micafungin Sodium for Prophylaxis Against Invasive Fungal Disease During Neutropenia in Pediatric & Adolescent Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT01135589 Phase 4 Micafungin
8 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
9 Validation of Central Venous (Port A Cath®) Blood Draws for Ciprofloxacin Pharmacokinetic Research in Patients Under Treatment for Childhood Cancer Unknown status NCT02967341 Phase 4
10 G-CSF (Filgrastim) or Pegfilgrastim Secondary Prophylaxis In The Adjuvant Chemotherapy Of Early Breast Cancer Unknown status NCT00030758 Phase 4
11 Optimal Timing and Duration of Daily G-CSF With Adjuvant TAC Chemotherapy in Node-positive Breast Cancer;Multicenter, Randomized, Open Label, Clinically IV Phase Unknown status NCT01571518 Phase 4 late leukostim;early leukostim
12 Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients Completed NCT01114165 Phase 4
13 Health Economic Evaluation of Rapid Detection of Bacteraemia and Fungemia by Real Time PCR for Cases of Febrile Neutropenia, Suspicion of Endocarditis and Severe Sepsis in Intensive Care Units Completed NCT00709358 Phase 4
14 Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients Completed NCT00454272 Phase 4 Teicoplanin;Vancomycin
15 Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever in Pediatric Acute Leukemia: Review of Temperature and Absolute Neutrophil Completed NCT04187755 Phase 4 Ceftazidime Injection;Cefepime Injection
16 Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With Fever of Unknown Origin: a Randomized Multicenter Non-inferiority Trial. Completed NCT02149329 Phase 4 Discontinuation of imipenem-cilastatin or meropenem
17 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Completed NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
18 A Multi Centre Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (REaCT-G2) Completed NCT02816164 Phase 4 Neupogen
19 A Multi-Centre Study to Compare Granulocyte-colony Stimulating Factors to Antibiotics for Primary Prophylaxis of Taxotere/Cyclophosphamide-Induced Febrile Neutropenia REaCT-TC2 Completed NCT02816112 Phase 4 Ciprofloxacin;Neupogen
20 Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients With Possible Bacterial Infection Completed NCT01401010 Phase 4 Doripenem;doripenem
21 Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia Following Administration by 4-hour Infusion and Bolus Injection. Completed NCT02213783 Phase 4 Imipenem
22 Randomized Open Label Clinical Trial Directed to Optimize the Duration of Empirical Antimicrobial Therapy in Haematologic Patients With Febrile Neutropenia Completed NCT01581333 Phase 4 Empirical antimicrobial treatment discontinuation;Standard empirical antimicrobial treatment discontinuation
23 Study on the Efficacy and Safety of 4.5mg Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer Completed NCT04009941 Phase 4 PEG-rhG-CSF
24 A Phase IV Clinical Trial of Patients With Solid Tumours Receiving Granocyte 34 (Granulocyte Colony Stimulating Factor (G-CSF)) as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Taxotere (Docetaxel) Based Regimen Completed NCT01107756 Phase 4 LENOGRASTIM (GRANOGYTE 34)
25 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
26 A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context. Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
27 A Multi-center, Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia in Patients With Breast Cancer Receiving Chemotherapy Completed NCT02805205 Phase 4 PEG-rhG-CSF
28 The Multi-center, Open-label,Randomized Comparison Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia in Patients With Breast Cancer Receiving Chemotherapy Completed NCT02805153 Phase 4 PEG-rhG-CSF;rhG-CSF
29 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
30 Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for Primary Prophylaxis of Taxotere/Cyclophosphamide-Induces Febrile Neutropenia Completed NCT02173262 Phase 4 G-CSF;Ciprofloxacin
31 Steady-State Comparative Bioavailability Study in Patients Requiring Anti-Fungal Prophylaxis Comparing Twice a Day Dosing of Lozanoc® (Mayne) Regardless of Food With Sporanox® (Janssen) Under Fed Conditions Completed NCT02621905 Phase 4 Sporanox;Lozanoc
32 A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection Completed NCT00686543 Phase 4 Posaconazole
33 A Multicenter, Open-label, Phase 4 Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy Completed NCT00125723 Phase 4
34 Safety of Cotrimoxazole in HIV- and HAART-exposed Infants in Botswana Completed NCT01086878 Phase 4 cotrimoxazole
35 Tobramycin én Gang Daglig Mot Tre Ganger Daglig, Gitt Med Benzylpenicillin, Til Pasienter Med nøytropen Feber Completed NCT00257790 Phase 4 Tobramycin once a day
36 A Randomized, Open Label, Multicenter Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
37 Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Haematologic Patients: a Randomised, Multicentre, Open-label, Superiority Clinical Trial (BEATLE) Recruiting NCT04233996 Phase 4 Piperacillin-Tazobactam 4 g-0.5 g;Cefepime 2000 mg;Meropenem 1000 mg
38 Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia Recruiting NCT04948463 Phase 4 Piperacillin and Tazobactam for Injection;Cefepime Injection;Ceftazidime Injection;Vancomycin Injection;Amikacin Injection;Ciprofloxacin
39 Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia Recruiting NCT05133310 Phase 4 Simvastatin
40 Evaluation of the Tolerability and Clinical Effectiveness of Letermovir in Heart Transplantation Recruiting NCT04904614 Phase 4 Letermovir
41 Fast-track Absolute Neutrophil Count in Suspected Neutropenic Fever (The FRANCiS-NF Trial): A Single-centre, Pragmatic, Open-label, Randomised, Controlled Trial Recruiting NCT05393505 Phase 4 Meropenem Injection;Levofloxacin;Amoxicillin Clavulanate;Antibiotic
42 CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients; a Single-arm, Single-center, Open-label Clinical Trial (CEF-10 Study) Not yet recruiting NCT05061654 Phase 4 Ceftolozane-tazobactam IV
43 A Pilot Trial of the Tolerability and Clinical Effectiveness of Letermovir When Used for Secondary Prophylaxis to Prevent Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients Not yet recruiting NCT05626530 Phase 4 Letermovir
44 Phase III Study of 3 Sequential Doses (10 mg/kg, 5 mg/kg, and 5 mg/kg) vs 3 mg/kg/Day of AmBisome® in the Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics Terminated NCT00421187 Phase 4 Liposomal amphotericin B (AmBisome®)
45 Twelve-month Study on the Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia Terminated NCT01859637 Phase 4
46 A Randomized Clinical Trial Comparing Two Management Strategies for Treatment of Neutropenia and Anemia Associated With Pegylated Interferon Plus Ribavirin Treatment of Compensated Chronic Hepatitis C in Adult Subjects Infected With HIV. Terminated NCT00194857 Phase 4 erythropoietin, GCSF
47 Subcutaneous (SC) vs. Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients: Randomized Controlled Trial Terminated NCT01222819 Phase 4 filgrastim
48 The Strategy Antifungal Empirical Traditional is Again Justified in Prolonged Neutropenias ". Study "PREVERT" Terminated NCT00190463 Phase 4 Amphotericin B
49 Long-acting Versus Short-acting Granulocyte Colony Stimulating Factor for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer Patients: A Multicenter Phase 3 Randomized Controlled Study Unknown status NCT04101760 Phase 3 Long-acting granulocyte colony stimulating factor;Short-acting granulocyte colony stimulating factor
50 A Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Evaluating the Prophylactic Use of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) on the Incidence of Neutropenia in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated With Myelosuppressive Chemotherapy Unknown status NCT01560195 Phase 3 Pegylated rhG-CSF: 100µg/kg;Pegylated rhG-CSF: 6mg;placebo and rhG-CSF 5ug/kg/d

Search NIH Clinical Center for Neutropenia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ciprofloxacin
Filgrastim
FILGRASTIM-SNDZ
Immunoglobulins, Intravenous
Itraconazole
pegfilgrastim
sargramostim

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Neutropenia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Neutropenia:
Hematopoietic stem cell transplantation for the treatment of genetic blood cell-related diseases
Embryonic/Adult Cultured Cells Related to Neutropenia:
Bone marrow-derived hematopoietic stem cells (family)
Umbilical cord blood-derived hematopoietic stem cells (family)

Cochrane evidence based reviews: neutropenia

Sources

Genetic Tests for Neutropenia

About this section

Genetic tests related to Neutropenia:

# Genetic test Affiliating Genes
1 Neutropenia 28
Sources

Anatomical Context for Neutropenia

About this section

Organs/tissues related to Neutropenia:

MalaCards : Breast, Bone Marrow, Myeloid, Lung, Neutrophil, Bone, Prostate
Sources

Publications for Neutropenia

About this section

Articles related to Neutropenia:

(show top 50) (show all 30268)
# Title Authors PMID Year
1
Whole-genome sequencing of patients with rare diseases in a national health system. 5
32581362 2020
2
Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents. 53 62
20175767 2010
3
Granulocyte colony-stimulating factor in toxic epidermal necrolysis (TEN) and Chelsea & Westminster TEN management protocol [corrected]. 53 62
19912214 2010
4
Circadian rhythm of neutrophil counts and granulocyte macrophage-colony stimulating factor (GM-CSF) under clozapine treatment: a case report. 53 62
19396726 2010
5
Genetic insights into congenital neutropenia. 53 62
19440858 2010
6
Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer. 53 62
19786849 2010
7
Which role for rituximab in hairy cell leukemia? Reflections on six cases. 53 62
20051682 2010
8
Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. 53 62
20021291 2010
9
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. 53 62
19297346 2010
10
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. 53 62
19932054 2010
11
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. 53 62
20068078 2010
12
Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1. 53 62
19608554 2009
13
Granulocyte colony-stimulating factor receptor: stimulating granulopoiesis and much more. 53 62
19699815 2009
14
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. 53 62
19556318 2009
15
G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence. 53 62
19916175 2009
16
Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. 53 62
19696793 2009
17
G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia. 53 62
19794089 2009
18
A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. 53 62
19770418 2009
19
SBDS expression and localization at the mitotic spindle in human myeloid progenitors. 53 62
19759903 2009
20
Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. 53 62
19756005 2009
21
A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia. 53 62
19457938 2009
22
Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma. 53 62
19446318 2009
23
[Allelic variants of TPMT and the risk of leucopenia and neutropenia in patients treated for acute leukaemia]. 53 62
20081263 2009
24
Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. 53 62
19513514 2009
25
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. 53 62
19604089 2009
26
[Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI]. 53 62
19620808 2009
27
Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. 53 62
19435433 2009
28
Complement factors C3a and C5a have distinct hemodynamic effects in the rat. 53 62
19285573 2009
29
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. 53 62
19438482 2009
30
Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients. 53 62
19200137 2009
31
XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. 53 62
19404210 2009
32
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. 53 62
19707503 2009
33
Neutropenia in congenital nephrotic syndrome of the Finnish type: role of urinary ceruloplasmin loss. 53 62
19423745 2009
34
Ela2 mutations and clinical manifestations in familial congenital neutropenia. 53 62
19415009 2009
35
A novel mutation in the G4.5 (TAZ) gene in a Greek patient with Barth syndrome. 53 62
19261493 2009
36
A novel neutrophil-specific PET imaging agent: cFLFLFK-PEG-64Cu. 53 62
19372473 2009
37
UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. 53 62
19450125 2009
38
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. 53 62
19390945 2009
39
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). 53 62
19242368 2009
40
Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases. 53 62
19151787 2009
41
Cardiolipin and monolysocardiolipin analysis in fibroblasts, lymphocytes, and tissues using high-performance liquid chromatography-mass spectrometry as a diagnostic test for Barth syndrome. 53 62
19454236 2009
42
XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. 53 62
19347726 2009
43
Shwachman-Diamond syndrome neutrophils have altered chemoattractant-induced F-actin polymerization and polarization characteristics. 53 62
19211642 2009
44
[Autoimmune thrombocytopenia, neutropenia and hemolysis]. 53 62
19225748 2009
45
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. 53 62
18685564 2009
46
Congenital neutropenia. 53 62
20008220 2009
47
Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. 53 62
19160320 2009
48
Mitochondrial defects lie at the basis of neutropenia in Barth syndrome. 53 62
19057200 2009
49
Mutations of the Wiskott-Aldrich Syndrome Protein affect protein expression and dictate the clinical phenotypes. 53 62
19082760 2009
50
Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. 53 62
19147084 2009
Sources

Variations for Neutropenia

About this section

ClinVar genetic disease variations for Neutropenia:

5 (show all 31)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 VPS13B NM_152564.5(VPS13B):c.11239C>T (p.Gln3747Ter) SNV Pathogenic
 56635 rs386834061 GRCh37: 8:100880540-100880540
GRCh38: 8:99868312-99868312
2 ELANE NM_001972.4(ELANE):c.597+5G>A SNV Pathogenic
 245598 rs879253882 GRCh37: 19:855799-855799
GRCh38: 19:855799-855799
3 CLPB NM_001258392.3(CLPB):c.1159C>T (p.Arg387Ter) SNV Pathogenic
 187786 rs200203460 GRCh37: 11:72013356-72013356
GRCh38: 11:72302312-72302312
4 VPS13B NM_152564.5(VPS13B):c.4545del (p.Ser1516fs) DEL Pathogenic
 374163 rs1057518939 GRCh37: 8:100523652-100523652
GRCh38: 8:99511424-99511424
5 CLPB NM_001258392.3(CLPB):c.1167+5G>A SNV Pathogenic
 1684623 GRCh37: 11:72013343-72013343
GRCh38: 11:72302299-72302299
6 HAX1 NM_006118.4(HAX1):c.182T>G (p.Phe61Cys) SNV Likely Pathogenic
 812887 rs146452018 GRCh37: 1:154245940-154245940
GRCh38: 1:154273464-154273464
7 ANKRD11 NM_013275.6(ANKRD11):c.6349_6362del (p.Pro2117fs) DEL Likely Pathogenic
 1301867 GRCh37: 16:89346588-89346601
GRCh38: 16:89280180-89280193
8 SLC37A4 NM_001164277.2(SLC37A4):c.81T>A (p.Asn27Lys) SNV Likely Pathogenic
 68290 rs193302889 GRCh37: 11:118899999-118899999
GRCh38: 11:119029289-119029289
9 PKP3 NM_007183.4(PKP3):c.118C>T (p.Arg40Trp) SNV Uncertain Significance
 1679868 GRCh37: 11:394410-394410
GRCh38: 11:394410-394410
10 LIMS2 NM_001161403.3(LIMS2):c.802+1G>A SNV Uncertain Significance
 1679869 GRCh37: 2:128397844-128397844
GRCh38: 2:127640269-127640269
11 USP3 NM_006537.4(USP3):c.941T>G (p.Phe314Cys) SNV Uncertain Significance
 1679870 GRCh37: 15:63866277-63866277
GRCh38: 15:63574078-63574078
12 VPS16 NM_022575.4(VPS16):c.540G>T (p.Trp180Cys) SNV Uncertain Significance
 932238 rs2089219111 GRCh37: 20:2841419-2841419
GRCh38: 20:2860773-2860773
13 XDH NM_000379.4(XDH):c.1172C>T (p.Pro391Leu) SNV Uncertain Significance
 598996 rs1558697792 GRCh37: 2:31602803-31602803
GRCh38: 2:31379937-31379937
14 XDH NM_000379.4(XDH):c.3647C>A (p.Pro1216His) SNV Uncertain Significance
 335760 rs143981573 GRCh37: 2:31562482-31562482
GRCh38: 2:31339616-31339616
15 RNF128 NM_194463.2(RNF128):c.917C>G (p.Pro306Arg) SNV Uncertain Significance
 1684522 GRCh37: X:106033445-106033445
GRCh38: X:106790215-106790215
16 C16orf92 NM_001109659.2(C16orf92):c.128G>A (p.Arg43Lys) SNV Likely Benign
 1679864 GRCh37: 16:30035111-30035111
GRCh38: 16:30023790-30023790
17 ZC3H3 NM_015117.3(ZC3H3):c.1203G>C (p.Lys401Asn) SNV Likely Benign
 1679863 GRCh37: 8:144620334-144620334
GRCh38: 8:143538164-143538164
18 ZC3H3 NM_015117.3(ZC3H3):c.1646C>T (p.Ser549Leu) SNV Likely Benign
 1679862 GRCh37: 8:144589985-144589985
GRCh38: 8:143507815-143507815
19 TLE2 NM_003260.5(TLE2):c.946G>A (p.Gly316Arg) SNV Likely Benign
 1679861 GRCh37: 19:3011086-3011086
GRCh38: 19:3011088-3011088
20 TLE2 NM_003260.5(TLE2):c.2114G>A (p.Ser705Asn) SNV Likely Benign
 1679860 GRCh37: 19:3000655-3000655
GRCh38: 19:3000657-3000657
21 MUC16 NM_024690.2(MUC16):c.27619T>C (p.Ser9207Pro) SNV Likely Benign
 1679859 GRCh37: 19:9059827-9059827
GRCh38: 19:8949151-8949151
22 CFB NM_001710.6(CFB):c.1942A>T (p.Lys648Ter) SNV Likely Benign
 1679858 GRCh37: 6:31919007-31919007
GRCh38: 6:31951230-31951230
23 MAGEC1 NM_005462.5(MAGEC1):c.2T>C (p.Met1Thr) SNV Likely Benign
 1679865 GRCh37: X:140992860-140992860
GRCh38: X:141905074-141905074
24 CHD1L NM_004284.6(CHD1L):c.1954G>A (p.Ala652Thr) SNV Likely Benign
 1679866 GRCh37: 1:146757100-146757100
GRCh38: 1:147285423-147285423
25 POLR3C NM_006468.8(POLR3C):c.251G>A (p.Arg84Gln) SNV Likely Benign
 932519 rs115748902 GRCh37: 1:145608556-145608556
GRCh38: 1:145826557-145826557
26 CCNQ NM_152274.5(CCNQ):c.338G>A (p.Arg113His) SNV Likely Benign
 703138 rs150562029 GRCh37: X:152860096-152860096
GRCh38: X:153594638-153594638
27 ATP6AP1 NM_001183.6(ATP6AP1):c.539G>A (p.Arg180His) SNV Likely Benign
 718379 rs140841742 GRCh37: X:153660787-153660787
GRCh38: X:154432441-154432441
28 KIF11 NM_004523.4(KIF11):c.77+5G>C SNV Likely Benign
 726756 rs200188195 GRCh37: 10:94353214-94353214
GRCh38: 10:92593457-92593457
29 KIF11 NM_004523.4(KIF11):c.3053A>G (p.His1018Arg) SNV Likely Benign
 1043778 rs147164679 GRCh37: 10:94413435-94413435
GRCh38: 10:92653678-92653678
30 EPHX1, TMEM63A NM_001136018.4(EPHX1):c.1004C>T (p.Thr335Met) SNV Benign
 1679867 GRCh37: 1:226030139-226030139
GRCh38: 1:225842438-225842438
31 SLC34A1 NM_003052.5(SLC34A1):c.284G>A (p.Arg95His) SNV Benign
 252613 rs145798898 GRCh37: 5:176813246-176813246
GRCh38: 5:177386245-177386245
Sources

Expression for Neutropenia

About this section
Search GEO for disease gene expression data for Neutropenia.
Sources

Pathways for Neutropenia

About this section

Pathways related to Neutropenia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Hematopoietic Stem Cells and Lineage-specific Markers 65
11.32 IL3 CSF3R CSF3 CSF2
2
Other interleukin signaling 66
10.54 CSF3R CSF3
3
Cytokines and inflammatory response 74
10.26 IL3 CSF3 CSF2
Sources

GO Terms for Neutropenia

About this section

Biological processes related to Neutropenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neutrophil differentiation GO:0030223 9.46 JAGN1 CSF2
2 negative regulation of chemokine production GO:0032682 9.43 SLC37A4 ELANE
3 glucose-6-phosphate transport GO:0015760 9.26 SLC37A4 G6PC3
4 granulocyte differentiation GO:0030851 9.02 SRP54 CSF3 CLPB
Sources

Sources for Neutropenia

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....